Mild cognitive impairment is a stage that occurs between normal ageing and dementia, marking a transition from one to the other.

Mild Cognitive Impairment: A Transitional Zone between Normal Function and Alzheimer’s Disease

Mild cognitive impairment (MCI) is a clinical syndrome that describes individuals who do not meet the criteria for dementia but have a high risk of progressing to a dementia disorder. MCI is a transitional zone between normal cognitive function and clinically probable Alzheimer’s disease (AD). The diagnosis of MCI is based on self and/of informant report and impairment on objective cognitive tasks, evidence of decline over time on objective cognitive tasks, and preserved basic activities of daily living/minimal impairment in complex instrumental functions.

When individuals with MCI are followed over time, some progress to AD and other dementia types, while others remain stable of even recover. The principal cognitive impairment can be amnestic, single non-memory domain, of involving multiple cognitive domains. There is evidence that deficits in regional cerebral blood flow and regional cerebral glucose metabolism could predict future development of AD in individuals with MCI.

Currently, there is no evidence for long-term efficacy of approved pharmacological treatments in MCI. However, epidemiological studies have indicated a reduced risk of dementia in individuals taking antihypertensive medications, cholesterol-lowering drugs, antioxidants, anti-inflammatories, and estrogen therapy. Randomized clinical trials are needed to verify these associations.

Two clinical screening instruments, the CAMCog (part of the CAMDEX) and the SISCO (part of the SIDAM), allow for a broad assessment of mild cognitive impairment. MCI represents a critical stage in the progression of cognitive decline and highlights the importance of early detection and intervention.

The primary distinction between delirium and dementia is the variability of consciousness levels.

Delirium (also known as acute confusional state) is a condition characterized by a sudden decline in consciousness and cognition, with a particular impairment in attention. It often involves perceptual disturbances, abnormal psychomotor activity, and sleep-wake cycle impairment. Delirium typically develops over a few days and has a fluctuating course. The causes of delirium are varied, ranging from metabolic disturbances to medications. It is important to differentiate delirium from dementia, as delirium has a brief onset, early disorientation, clouding of consciousness, fluctuating course, and early psychomotor changes. Delirium can be classified into three subtypes: hypoactive, hyperactive, and mixed. Patients with hyperactive delirium demonstrate restlessness, agitation, and hyper vigilance, while those with hypoactive delirium present with lethargy and sedation. Mixed delirium demonstrates both hyperactive and hypoactive features. The hypoactive form is most common in elderly patients and is often misdiagnosed as depression of dementia.

Dosages of donepezil exceeding 10 mg are not recommended, as his Alzheimer’s has advanced from mild to moderate. NICE recommends incorporating memantine alongside an AChE-I at this stage.

Treatment of Dementia: AChE Inhibitors and Memantine

Dementia is a debilitating condition that affects millions of people worldwide. Acetylcholinesterase inhibitors (AChE inhibitors) and memantine are two drugs used in the management of dementia. AChE inhibitors prevent cholinesterase from breaking down acetylcholine, which is deficient in Alzheimer’s due to loss of cholinergic neurons. Donepezil, galantamine, and rivastigmine are AChE inhibitors used in the management of Alzheimer’s. Memantine is an NMDA receptor antagonist that blocks the effects of pathologically elevated levels of glutamate that may lead to neuronal dysfunction.

NICE guidelines recommend the use of AChE inhibitors for managing mild to moderate Alzheimer’s and memantine for managing moderate to severe Alzheimer’s. For those already taking an AChE inhibitor, memantine can be added if the disease is moderate of severe. AChE inhibitors are also recommended for managing mild, moderate, and severe dementia with Lewy bodies, while memantine is considered if AChE inhibitors are not tolerated of contraindicated. AChE inhibitors and memantine are not recommended for vascular dementia, frontotemporal dementia, of cognitive impairment due to multiple sclerosis.

The British Association for Psychopharmacology recommends AChE inhibitors as the first choice for Alzheimer’s and mixed dementia, while memantine is the second choice. AChE inhibitors and memantine are also recommended for dementia with Parkinson’s and dementia with Lewy bodies.

In summary, AChE inhibitors and memantine are important drugs used in the management of dementia. The choice of drug depends on the type and severity of dementia, as well as individual patient factors.

The individual is displaying a visual representation of hydrocephalus, which may result from a past intracranial hemorrhage that obstructs the flow of cerebrospinal fluid (CSF) due to debris. Periventricular lucency (PL) in hydrocephalus is a result of either acute edema of chronic retention of CSF in the periventricular white matter, caused by an increase in water content. This phenomenon can be partially reversed and may serve as an indication for a shunt.

Pathological Crying

Pathological crying, also known as pseudobulbar affect, is a condition characterized by sudden outbursts of crying of laughing in response to minor stimuli without any changes in mood. This condition can occur in response to nonspecific and inconsequential stimuli, and lacks a clear association with the prevailing mood state. Pathological crying can result from various neurological conditions, including strokes and multiple sclerosis.

When it comes to treating pathological crying post-stroke, citalopram is often the recommended treatment due to its efficacy in open label studies. The Maudsley Guidelines suggest that TCAs of SSRIs may be effective for MS, while valproic acid and the combination of dextromethorphan and low dose quinidine have also shown efficacy.

Understanding the neuroanatomy of pathological laughing and crying is important for diagnosing and treating this condition. Further research is needed to better understand the underlying mechanisms and develop more effective treatments.

Huntington’s disease is categorized as a type of dementia that affects the subcortical region of the brain. Cognitive decline is a prominent feature of the disease and typically manifests early on. However, the use of acetylcholinesterase inhibitors has not been shown to improve cognitive function in individuals with Huntington’s disease. A study published in Neurology in 2008 investigated the effects of donepezil on both motor and cognitive function in individuals with Huntington’s disease. The results showed no significant improvement in either area.

Psychiatric and Behavioural Symptoms of Huntington’s Disease

Huntington’s disease is a condition that affects individuals with a triad of symptoms, including motor, cognitive, and psychiatric symptoms. While the symptoms typically begin in the third and fourth decades of life, individuals with a high number of CAG repeats may experience symptoms before the age of 20, known as juvenile Huntington’s disease.

The psychiatric symptoms of Huntington’s disease can include depression, apathy, dementia, psychosis, anxiety, mania, sexual dysfunction, and even suicide. These symptoms can significantly impact an individual’s quality of life and require appropriate treatment. Advances in psychiatric treatment have been made to address these symptoms and improve the overall well-being of individuals with Huntington’s disease.

Benzodiazepines with a longer duration of action, such as diazepam, pose more difficulties than those with a shorter duration of action.

Risk Factors for Delirium

Delirium is a common condition that affects many elderly individuals. There are several risk factors that can increase the likelihood of developing delirium. These risk factors include age, cognitive impairment, severe medical illness, previous history of delirium of neurological disease, psychoactive drug use, polypharmacy, and anticholinergic drug use.

Medications are the most common reversible cause of delirium and dementia in the elderly. Certain classes of drugs, such as opioids, benzodiazepines, and anticholinergics, are strongly associated with the development of drug-induced dementia. Long-acting benzodiazepines are more troublesome than shorter-acting ones. Opioids are associated with an approximately 2-fold increased risk of delirium in medical and surgical patients. Pethidine, a member of the opioid class, appears to have a higher risk of delirium compared with other opioids due to its accumulation in individuals with impaired renal function and conversion to a metabolite with anticholinergic properties.

Overall, it is important to be aware of these risk factors and to carefully monitor medication use in elderly individuals to prevent the development of delirium.

Risperidone is the sole atypical antipsychotic approved for managing short-term aggression in dementia patients who have not responded to behavioral interventions. However, antipsychotics carry risks of adverse effects, including heightened confusion and falls. In elderly individuals, traditional antipsychotics may cause extrapyramidal side effects and QTc prolongation.

Mild cognitive impairment (MCI) is a condition where individuals experience cognitive impairment but are still able to perform daily activities with minimal difficulty. However, those with MCI are at a higher risk of developing dementia compared to those without the condition. While there are currently no pharmacological options available, regular exercise has been shown to be the most effective intervention for MCI. It is important to note that some individuals with MCI may remain stable of even return to normal neurological function. These findings were reported in a practice guideline update summary by Peterson in the journal Neurology.

Treatment of Dementia: AChE Inhibitors and Memantine

Dementia is a debilitating condition that affects millions of people worldwide. Acetylcholinesterase inhibitors (AChE inhibitors) and memantine are two drugs used in the management of dementia. AChE inhibitors prevent cholinesterase from breaking down acetylcholine, which is deficient in Alzheimer’s due to loss of cholinergic neurons. Donepezil, galantamine, and rivastigmine are AChE inhibitors used in the management of Alzheimer’s. Memantine is an NMDA receptor antagonist that blocks the effects of pathologically elevated levels of glutamate that may lead to neuronal dysfunction.

NICE guidelines recommend the use of AChE inhibitors for managing mild to moderate Alzheimer’s and memantine for managing moderate to severe Alzheimer’s. For those already taking an AChE inhibitor, memantine can be added if the disease is moderate of severe. AChE inhibitors are also recommended for managing mild, moderate, and severe dementia with Lewy bodies, while memantine is considered if AChE inhibitors are not tolerated of contraindicated. AChE inhibitors and memantine are not recommended for vascular dementia, frontotemporal dementia, of cognitive impairment due to multiple sclerosis.

The British Association for Psychopharmacology recommends AChE inhibitors as the first choice for Alzheimer’s and mixed dementia, while memantine is the second choice. AChE inhibitors and memantine are also recommended for dementia with Parkinson’s and dementia with Lewy bodies.

In summary, AChE inhibitors and memantine are important drugs used in the management of dementia. The choice of drug depends on the type and severity of dementia, as well as individual patient factors.

DLB is typically diagnosed when cognitive impairments of hallucinations occur before of within one year of Parkinsonism onset, while Parkinson’s disease dementia is diagnosed when Parkinsonism precedes dementia by more than a year. Neither vascular nor frontotemporal dementia typically present with psychosis of neuroleptic sensitivity. Pseudo-dementia refers to cases of depression that mimic dementia, but there is no indication of depression in the given scenario. It is crucial to identify depression when present to provide timely treatment and avoid unnecessary investigations.

Lewy body dementia is a type of dementia that is becoming more recognized and accounts for up to 20% of cases. It is characterized by the presence of alpha-synuclein cytoplasmic inclusions (Lewy bodies) in certain areas of the brain. The relationship between Parkinson’s disease and Lewy body dementia is complex, as dementia is often seen in Parkinson’s disease and up to 40% of Alzheimer’s patients have Lewy bodies. Neuroleptics should be avoided in Lewy body dementia, except in cases of psychosis of aggression. Cholinesterase inhibitors are the first line of treatment for psychosis with Lewy body dementia, and antipsychotics are the second line. Clozapine is the preferred antipsychotic for Lewy body dementia, but if it is not appropriate, quetiapine is a reasonable choice. The features of Lewy body dementia include progressive cognitive impairment, parkinsonism, visual hallucinations, and other symptoms such as delusions and non-visual hallucinations. Additional features that support the diagnosis include fluctuating cognition, repeated falls, syncope, and neuroleptic sensitivity. Diagnosis is usually clinical, but single-photon emission computed tomography (SPECT) is increasingly used with a sensitivity of around 90% and a specificity of 100%.

Given the atrophy of the medial temporal lobe that is linked to Alzheimer’s, a reduction in perfusion of the temporal lobe would be anticipated.

SPECT Imaging for Alzheimer’s Diagnosis

SPECT imaging has been found to be a useful tool in differentiating between patients with Alzheimer’s disease and healthy older individuals. Studies have shown that temporal and parietal hypoperfusion can be indicative of Alzheimer’s disease. Additionally, SPECT imaging has been effective in distinguishing between Alzheimer’s disease and Lewy body dementia. A SPECT scan of a patient with Alzheimer’s disease versus one with Lewy body dementia showed lower perfusion in medial temporal areas for Alzheimer’s disease and lower perfusion in occipital cortex for Lewy body dementia. These findings suggest that SPECT imaging can be a valuable diagnostic tool for Alzheimer’s disease and related dementias.

The Maudsley Guidelines recommend trying Donepezil. Melatonin is only recommended for sleep disturbances, while Diazepam, Amitriptyline, and Valproate are not recommended.

Management of Non-Cognitive Symptoms in Dementia

Non-cognitive symptoms of dementia can include agitation, aggression, distress, psychosis, depression, anxiety, sleep problems, wandering, hoarding, sexual disinhibition, apathy, and shouting. Non-pharmacological measures, such as music therapy, should be considered before prescribing medication. Pain may cause agitation, so a trial of analgesics is recommended. Antipsychotics, such as risperidone, olanzapine, and aripiprazole, may be used for severe distress of serious risk to others, but their use is controversial due to issues of tolerability and an association with increased mortality. Cognitive enhancers, such as AChE-Is and memantine, may have a modest benefit on BPSD, but their effects may take 3-6 months to take effect. Benzodiazepines should be avoided except in emergencies, and antidepressants, such as citalopram and trazodone, may have mixed evidence for BPSD. Mood stabilizers, such as valproate and carbamazepine, have limited evidence to support their use. Sedating antihistamines, such as promethazine, may cause cognitive impairment and should only be used short-term. Melatonin has limited evidence to support its use but is safe to use and may be justified in some cases where benefits are seen. For Lewy Body dementia, clozapine is favored over risperidone, and quetiapine may be a reasonable choice if clozapine is not appropriate. Overall, medication should only be used when non-pharmacological measures are ineffective, and the need is balanced with the increased risk of adverse effects.

Psychiatric and Behavioural Symptoms of Huntington’s Disease

Huntington’s disease is a condition that affects individuals with a triad of symptoms, including motor, cognitive, and psychiatric symptoms. While the symptoms typically begin in the third and fourth decades of life, individuals with a high number of CAG repeats may experience symptoms before the age of 20, known as juvenile Huntington’s disease.

The psychiatric symptoms of Huntington’s disease can include depression, apathy, dementia, psychosis, anxiety, mania, sexual dysfunction, and even suicide. These symptoms can significantly impact an individual’s quality of life and require appropriate treatment. Advances in psychiatric treatment have been made to address these symptoms and improve the overall well-being of individuals with Huntington’s disease.

Charles Bonnet syndrome is a condition that is not yet fully understood. It typically affects elderly individuals with visual impairment, causing them to experience complex visual hallucinations while still maintaining full awareness. These hallucinations are often pleasant and pastoral in nature and may be alleviated with reassurance. Unfortunately, there is currently no medical treatment available for this condition. Some theories suggest that the lack of visual input to the brain may trigger dream-like hallucinations, similar to phantom limb pain. For more information on this topic, please refer to the article Charles Bonnet syndrome-elderly people and visual hallucinations by Jakob et al. (2004).

Transient Global Amnesia: Definition, Diagnostic Criteria, and Possible Causes

Transient global amnesia (TGA) is a clinical syndrome characterized by sudden and severe amnesia, often accompanied by repetitive questioning, that lasts for several hours. The term was first coined in 1964 by Fisher and Adams. To diagnose TGA, the following criteria have been established: (1) the attack must be witnessed, (2) there must be clear anterograde amnesia, (3) clouding of consciousness and loss of personal identity must be absent, (4) there should be no accompanying focal neurological symptoms, (5) epileptic features must be absent, (6) attacks must resolve within 24 hours, and (7) patients with recent head injury of known active epilepsy are excluded.

Epidemiological studies have shown that thromboembolic cerebrovascular disease does not play a role in the causation of TGA. However, the incidence of migraine in patients with TGA is higher than in the general population. A small minority of cases with unusually brief and recurrent attacks eventually manifest temporal lobe epilepsy. EEG recording is typically normal after an attack, even when performed during the attack.

Possible causes of TGA include venous congestion with Valsalva-like activities before symptom onset, arterial thromboembolic ischemia, and vasoconstriction due to hyperventilation. Precipitants of TGA often include exertion, cold, pain, emotional stress, and sexual intercourse.

Frontotemporal Lobar Degeneration

Frontotemporal lobar degeneration (FTLD) is a group of neurodegenerative disorders that involve the atrophy of the frontal and temporal lobes. The disease is characterized by progressive dysfunction in executive functioning, behavior, and language, and can mimic psychiatric disorders due to its prominent behavioral features. FTLD is the third most common form of dementia across all age groups and a leading type of early-onset dementia.

The disease has common features such as onset before 65, insidious onset, relatively preserved memory and visuospatial skills, personality change, and social conduct problems. There are three recognized subtypes of FTLD: behavioral-variant (bvFTD), language variant – primary progressive aphasia (PPA), and the language variant is further subdivided into semantic variant PPA (aka semantic dementia) and non-fluent agrammatic variant PPA (nfvPPA).

As the disease progresses, the symptoms of the three clinical variants can converge, as an initially focal degeneration becomes more diffuse and spreads to affect large regions in the frontal and temporal lobes. The key differences between the subtypes are summarized in the table provided. The bvFTD subtype is characterized by poor personal and social decorum, disinhibition, poor judgment and problem-solving, apathy, compulsive/perseverative behavior, hyperorality of dietary changes, and loss of empathy. The nfvPPA subtype is characterized by slow/slurred speech, decreased word output and phrase length, word-finding difficulties, apraxia of speech, and spared single-word comprehension. The svPPA subtype is characterized by intact speech fluency, word-finding difficulties (anomia), impaired single-word comprehension, repetitive speech, and reduced word comprehension.

In conclusion, FTLD is a progressive, heterogeneous, neurodegenerative disorder that affects the frontal and temporal lobes. The disease is characterized by dysfunction in executive functioning, behavior, and language, and can mimic psychiatric disorders due to its prominent behavioral features. There are three recognized subtypes of FTLD, and as the disease progresses, the symptoms of the three clinical variants can converge.

Agomelatine should be taken orally at bedtime, with a recommended starting dose of 25 mg once daily. The dose may be increased to 50 mg once daily. However, it is important to note that cases of liver injury, including hepatic failure, have been reported in patients taking agomelatine, particularly in those with pre-existing liver conditions. Liver function tests should be performed before starting treatment, and treatment should not be initiated if transaminases exceed 3 times the upper limit of normal. During treatment, transaminases should be monitored periodically at three weeks, six weeks (end of acute phase), twelve weeks, and twenty-four weeks (end of maintenance phase), and thereafter when clinically indicated. If transaminases exceed 3 times the upper limit of normal, treatment should be discontinued. When increasing the dosage, liver function tests should be performed at the same frequency as when initiating treatment.

Antidepressants in the Elderly: Maudsley Guidelines 14th Edition Summary

Antidepressants have a similar response rate in the elderly as in younger adults, but factors such as physical illness, anxiety, and reduced executive functioning can affect prognosis. SSRIs and TCAs are equally effective, but TCAs have higher withdrawal rates in the elderly. NICE recommends starting with an SSRI, then trying another SSRI of a newer generation antidepressant if there is no response. If this fails, an antidepressant from a different class can be considered, but caution is needed with TCAs and MAOIs due to adverse effects and drug interactions. There is no ideal antidepressant for elderly patients, and choice should be based on individual cases. SSRIs are generally better tolerated than TCAs, but increase the risk of gastrointestinal bleeds, hyponatremia, and falls. Agomelatine is effective and well-tolerated in older patients, but requires frequent liver function tests. Fish oils are probably not effective, and highly anticholinergic medicines increase the risk of dementia. Elderly patients may take longer to respond to antidepressants, and it is recommended that they continue taking them for at least 2 years following remission.

Individuals with PSP typically maintain an upright posture of may even lean their heads backwards (and have a tendency to fall backwards), whereas those with Parkinson’s disease tend to hunch forward.

Understanding Progressive Supranuclear Palsy

Progressive supranuclear palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a type of neurodegenerative disease that affects various aspects of a person’s health. This condition is characterized by problems with cognition, eye movements, and posture. One of the most notable features of PSP is the supranuclear gaze dysfunction, which primarily affects vertical gaze. Additionally, individuals with PSP may experience extrapyramidal symptoms and cognitive dysfunction. PSP typically develops after the age of 60, and unfortunately, there is currently no effective treatment available for this condition.

Epidemiology of Mental Disorders Among the Elderly

Depression:
Contrary to popular belief, studies have shown that rates of depression among the elderly in the general population are lower than in younger adults. However, elderly individuals who seek medical attention have a higher prevalence of depressive symptoms, with one study in London reporting a point prevalence of around 30%. Suicide risk factors in the elderly include a history of attempts, depressive disorder, access to lethal means, physical illness of disability, chronic pain, recent losses, and social isolation. Physician education in recognizing and treating depression and restricting access to lethal means have been found to reduce suicide rates.

Personality Disorder:
There is limited information on the prevalence of personality disorders in the general population, but rates tend to decrease with age.

Psychosis:
Very late-onset schizophrenia, with onset after the age of 60, has a 1-year prevalence of 0.1 to 0.5%. It is more common in women and has been associated with sensory impairment. Genetic factors appear to be less important than in earlier onset schizophrenia.

Alcohol Misuse:
Studies have shown that men have higher rates of alcohol misuse than women in the elderly population. However, precise figures and prevalence rates are unreliable, and standard assessment tools may not be valid in this group.

Dementia:
Dementia incidence is similar across all continents and regions of the world, with Alzheimer’s accounting for 60-70% and vascular dementia accounting for 15-20% of all dementia cases. Age is the strongest risk factor for dementia, with approximately 48% of people aged 95 and over having dementia.

The term used to refer to the individual who creates a will is the testator, which is why the ability to create a will is known as testamentary capacity (derived from the Latin word testator).

Testamentary Capacity

Testamentary capacity is a crucial aspect of common law that pertains to a person’s legal and mental ability to create a will. To meet the requirements for testamentary capacity, there are four key factors that a testator must be aware of at the time of making the will. These include knowing the extent and value of their property, identifying the natural beneficiaries, understanding the disposition they are making, and having a plan for how the property will be distributed.

Distinguishing Cortical and Subcortical Dementia: A Contested Area

Attempts have been made to differentiate between cortical and subcortical dementia based on clinical presentation, but this remains a contested area. Some argue that the distinction is not possible. Cortical dementia is characterized by impaired memory, visuospatial ability, executive function, and language. Examples of cortical dementias include Alzheimer’s disease, Pick’s disease, and Creutzfeldt-Jakob disease. On the other hand, subcortical dementia is characterized by general slowing of mental processes, personality changes, mood disorders, and abnormal movements. Examples of subcortical dementias include Binswanger’s disease, dementia associated with Huntington’s disease, AIDS, Parkinson’s disease, Wilson’s disease, and progressive supranuclear palsy. Despite ongoing debate, questions on this topic may appear in exams.

Transient Global Amnesia: Definition, Diagnostic Criteria, and Possible Causes

Transient global amnesia (TGA) is a clinical syndrome characterized by sudden and severe amnesia, often accompanied by repetitive questioning, that lasts for several hours. The term was first coined in 1964 by Fisher and Adams. To diagnose TGA, the following criteria have been established: (1) the attack must be witnessed, (2) there must be clear anterograde amnesia, (3) clouding of consciousness and loss of personal identity must be absent, (4) there should be no accompanying focal neurological symptoms, (5) epileptic features must be absent, (6) attacks must resolve within 24 hours, and (7) patients with recent head injury of known active epilepsy are excluded.

Epidemiological studies have shown that thromboembolic cerebrovascular disease does not play a role in the causation of TGA. However, the incidence of migraine in patients with TGA is higher than in the general population. A small minority of cases with unusually brief and recurrent attacks eventually manifest temporal lobe epilepsy. EEG recording is typically normal after an attack, even when performed during the attack.

Possible causes of TGA include venous congestion with Valsalva-like activities before symptom onset, arterial thromboembolic ischemia, and vasoconstriction due to hyperventilation. Precipitants of TGA often include exertion, cold, pain, emotional stress, and sexual intercourse.

Out of the given options, music therapy has the most compelling evidence to back up its effectiveness (Maudsley 14th). The remaining choices have either not demonstrated any positive outcomes of lack sufficient evidence to support their use.

Management of Non-Cognitive Symptoms in Dementia

Non-cognitive symptoms of dementia can include agitation, aggression, distress, psychosis, depression, anxiety, sleep problems, wandering, hoarding, sexual disinhibition, apathy, and shouting. Non-pharmacological measures, such as music therapy, should be considered before prescribing medication. Pain may cause agitation, so a trial of analgesics is recommended. Antipsychotics, such as risperidone, olanzapine, and aripiprazole, may be used for severe distress of serious risk to others, but their use is controversial due to issues of tolerability and an association with increased mortality. Cognitive enhancers, such as AChE-Is and memantine, may have a modest benefit on BPSD, but their effects may take 3-6 months to take effect. Benzodiazepines should be avoided except in emergencies, and antidepressants, such as citalopram and trazodone, may have mixed evidence for BPSD. Mood stabilizers, such as valproate and carbamazepine, have limited evidence to support their use. Sedating antihistamines, such as promethazine, may cause cognitive impairment and should only be used short-term. Melatonin has limited evidence to support its use but is safe to use and may be justified in some cases where benefits are seen. For Lewy Body dementia, clozapine is favored over risperidone, and quetiapine may be a reasonable choice if clozapine is not appropriate. Overall, medication should only be used when non-pharmacological measures are ineffective, and the need is balanced with the increased risk of adverse effects.

Dementia with Parkinson’s Disease: Understanding Cognitive Symptoms

Dementia with Parkinson’s disease is a syndrome that involves a decline in memory and other cognitive domains, leading to social and occupational dysfunction. Along with motor problems, non-motor symptoms such as cognitive, behavioral, and psychological issues can also arise. There is debate over whether Lewy body dementia and dementia due to Parkinson’s are different conditions. Drugs used to treat Parkinson’s can interfere with cognitive function, and people with this type of dementia tend to have marked problems with executive function. Cholinesterase inhibitors can improve cognitive performance, but they are not well tolerated and can cause side effects. Understanding the cognitive symptoms of dementia with Parkinson’s disease is crucial for effective clinical management.

Charles Bonnet Syndrome: A Condition of Complex Visual Hallucinations

Charles Bonnet Syndrome (CBS) is a condition characterized by persistent of recurrent complex visual hallucinations that occur in clear consciousness. This condition is observed in individuals who have suffered damage to the visual pathway, which can be caused by damage to any part of the pathway from the eye to the cortex. The hallucinations are thought to result from a release phenomenon secondary to the deafferentation of the cerebral cortex. CBS is equally distributed between sexes and does not show any familial predisposition. The most common ophthalmological conditions associated with this syndrome are age-related macular degeneration, followed by glaucoma and cataract.

Risk factors for CBS include advanced age, peripheral visual impairment, social isolation, sensory deprivation, and early cognitive impairment. Well-formed complex visual hallucinations are thought to occur in 10-30 percent of individuals with severe visual impairment. Only around a third of individuals find the hallucinations themselves an unpleasant or disturbing experience. The most effective treatment is reversal of the visual impairment. Antipsychotic drugs are commonly prescribed but are largely ineffective. CBS is a long-lasting condition, with 88% of individuals experiencing it for two years of more, and only 25% resolving at nine years.

Alice in Wonderland syndrome, also known as Todd syndrome, is a neurological disorder that causes distortions in a person’s perception of their body image, space, and time. This can lead to experiences such as Lilliputian hallucinations, macropsia, and altered sense of velocity. On the other hand, Diogenes syndrome is a condition commonly observed in the elderly, characterized by extreme self-neglect, social withdrawal, apathy, lack of shame, and compulsive hoarding of garbage. It is often linked to progressive dementia.

Charles Bonnet Syndrome: A Condition of Complex Visual Hallucinations

Charles Bonnet Syndrome (CBS) is a condition characterized by persistent of recurrent complex visual hallucinations that occur in clear consciousness. This condition is observed in individuals who have suffered damage to the visual pathway, which can be caused by damage to any part of the pathway from the eye to the cortex. The hallucinations are thought to result from a release phenomenon secondary to the deafferentation of the cerebral cortex. CBS is equally distributed between sexes and does not show any familial predisposition. The most common ophthalmological conditions associated with this syndrome are age-related macular degeneration, followed by glaucoma and cataract.

Risk factors for CBS include advanced age, peripheral visual impairment, social isolation, sensory deprivation, and early cognitive impairment. Well-formed complex visual hallucinations are thought to occur in 10-30 percent of individuals with severe visual impairment. Only around a third of individuals find the hallucinations themselves an unpleasant or disturbing experience. The most effective treatment is reversal of the visual impairment. Antipsychotic drugs are commonly prescribed but are largely ineffective. CBS is a long-lasting condition, with 88% of individuals experiencing it for two years of more, and only 25% resolving at nine years.

Dopamine Agonists

Dopamine receptor agonists are medications that directly affect dopamine receptors and are commonly used to treat Parkinson’s disease. Examples of these drugs include apomorphine and ropinirole. However, these medications are known to have psychiatric side effects, particularly impulse control disorders such as pathological gambling, binge eating, and hypersexuality. This information is according to the British National Formulary (BNF) from March 2012.

Management of Non-Cognitive Symptoms in Dementia

Non-cognitive symptoms of dementia can include agitation, aggression, distress, psychosis, depression, anxiety, sleep problems, wandering, hoarding, sexual disinhibition, apathy, and shouting. Non-pharmacological measures, such as music therapy, should be considered before prescribing medication. Pain may cause agitation, so a trial of analgesics is recommended. Antipsychotics, such as risperidone, olanzapine, and aripiprazole, may be used for severe distress of serious risk to others, but their use is controversial due to issues of tolerability and an association with increased mortality. Cognitive enhancers, such as AChE-Is and memantine, may have a modest benefit on BPSD, but their effects may take 3-6 months to take effect. Benzodiazepines should be avoided except in emergencies, and antidepressants, such as citalopram and trazodone, may have mixed evidence for BPSD. Mood stabilizers, such as valproate and carbamazepine, have limited evidence to support their use. Sedating antihistamines, such as promethazine, may cause cognitive impairment and should only be used short-term. Melatonin has limited evidence to support its use but is safe to use and may be justified in some cases where benefits are seen. For Lewy Body dementia, clozapine is favored over risperidone, and quetiapine may be a reasonable choice if clozapine is not appropriate. Overall, medication should only be used when non-pharmacological measures are ineffective, and the need is balanced with the increased risk of adverse effects.

Dementia Prevention

The NICE Guidelines on Dementia, 2006 (amended March 2011) state that certain interventions should not be recommended as specific treatments for the primary prevention of dementia. These interventions include statins, hormone replacement therapy, vitamin E, and non-steroidal anti-inflammatory drugs. It is important to note that while these interventions may have other health benefits, they should not be relied upon as a means of preventing dementia.

Despite the limited data available, the college remains interested in the topic. According to Harwood’s (2001) study, anankastic personality disorder appears to be more common among older individuals who die by suicide. The study was both descriptive and case-controlled. It was published in the International Journal of Geriatric Psychiatry and can be found in Volume 16, Issue 2, pages 155-165.

Suicide in the Elderly

Self-harm in older individuals should be approached with caution as approximately 20% of completed suicides occur in those over the age of 65. Studies have consistently found that more than half of those who commit suicide after the age of 65 are suffering from a depressive disorder at the time of death. Personality traits also appear to play a role, with an association between suicide in older individuals and anankastic (obsessional) and anxious personality traits observed in one study. Dissocial of borderline disorders are more commonly found in younger suicide victims. It is important to be aware of these factors when assessing and treating suicidal behavior in the elderly.